Breaking Finance News

Harvard Bioscience, Inc. (NASDAQ:HBIO) has been upgraded to Hold in a report by Zacks Investment Research earlier today.

Having a price of $2.88, Harvard Bioscience, Inc. (NASDAQ:HBIO) traded 1.05% higher on the day. The last stock price close is down -2.83% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $2.67 and a two hundred day average of $2.96. Trade Volume was down over the average, with 30,895 shares of HBIO changing hands under the typical 129,006

Zacks Investment Research has upgraded Harvard Bioscience, Inc. (NASDAQ:HBIO) to Hold in a statement released on 9/23/2016.

Recent Performance Chart

Harvard Bioscience, Inc. (NASDAQ:HBIO)

Harvard Bioscience, Inc. has 52 week low of $2.41 and a one year high of $4.24 and has a market cap of $0.

General Information About Harvard Bioscience, Inc. (NASDAQ:HBIO)

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company's products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company's product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company's products consist of instruments, consumables and systems that are made up of various individual products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *